(2R,3S,4S,5R)-2,3,4,5,6-pentahydroxyhexanal;(2R,3R,4S,5S,6R)-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3S,4S,5R)-2,3,4,5,6-pentahydroxyhexanal;(2R,3R,4S,5S,6R)-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxane-2,3,4,5-tetrol
• 化学式: C18H34O17
• 分子量: 522.5
• InChiKey: VEQPJFBVLXEZGU-KTTTZJDBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -8.78
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.94
• 拓扑面积：
  308
• 氢给体数：
  13
• 氢受体数：
  17

文献信息

• Compositions and methods for live, attenuated alphavirus formulations
  申请人：TAKEDA VACCINES, INC.

  公开号：US10137186B2

  公开（公告）日：2018-11-27

  Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.

  本文的实施方案涉及活的减毒α-病毒的组合物和方法。在某些实施方案中，减毒活病毒组合物包括但不限于一种或多种减毒活α病毒和减少减毒活α病毒失活和/或降解的组合物。在其他实施方案中，减毒活病毒组合物可以是疫苗组合物。在其它组合物中，减毒的活α-病毒组合物可包括 HEPES 缓冲液。在其他实施方案中，HEPES 缓冲液可进一步包括碳水化合物、明胶和/或盐。
• COMPOSITIONS AND METHODS FOR LIVE, ATTENUATED ALPHAVIRUS FORMULATIONS
  申请人：Takeda Vaccines, Inc.

  公开号：EP2968515B1

  公开（公告）日：2019-05-08
• US20140271715A1
  申请人：——

  公开号：US20140271715A1

  公开（公告）日：2014-09-18
• [EN] COMPOSITIONS AND METHODS FOR LIVE, ATTENUATED ALPHAVIRUS FORMULATIONS<br/>[FR] COMPOSITIONS ET PROCÉDÉS POUR FORMULATIONS D'ALPHAVIRUS ATTÉNUÉ VIVANT
  申请人：INVIRAGEN INC

  公开号：WO2014151855A1

  公开（公告）日：2014-09-25

  Embodiments herein relate to compositions of and methods for live attenuated alphaviruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated alphaviruses and compositions to reduce inactivation and/or degradation of the live, attenuated alphavirus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated alphavirus composition may include HEPES buffer. In other embodiments, the HEPES buffer may further include a carbohydrate and gelatin and/or a salt.